瑞典研究将Ozempic/Wegovy与降低抑郁,焦虑和药物滥用风险联系起来. Swedish study links Ozempic/Wegovy to lower depression, anxiety, and substance abuse risks.

2026年3月发表在"柳叶刀精神病学"杂志上的瑞典一项大型研究将GLP-1受体激动剂药物如Ozempic和Wegovy中使用的赛马格卢提德与恶化抑郁症,焦虑症和滥用毒品风险显著降低. A large Swedish study published in The Lancet Psychiatry in March 2026 links GLP-1 receptor agonist drugs like semaglutide, used in Ozempic and Wegovy, to significantly reduced risks of worsening depression, anxiety, and substance abuse. 在超过95,000名患有精神疾病的患者中,使用塞马格卢提德的人出现抑郁症恶化的风险降低了44%,焦虑症恶化风险下降了38%,与物质使用障碍相关住院病例减少了47%. Among over 95,000 patients with mental health conditions, semaglutide users saw a 44% lower risk of worsening depression and a 38% lower risk of worsening anxiety, along with a 47% drop in substance use disorder-related hospitalizations. 利拉格胺也对抑郁症有好处. Liraglutide also showed benefits for depression. 这些发现表明这些糖尿病和减肥药物可能有心理健康优势,尽管研究人员强调需要进一步的研究来确认因果关系并了解机制. The findings suggest potential mental health advantages for these diabetes and weight-loss medications, though researchers stress the need for further study to confirm causality and understand mechanisms.